bluebird bio Inc (NAS:BLUE)
$ 0.4171 0.0121 (2.99%) Market Cap: 81.10 Mil Enterprise Value: 376.50 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 31/100

bluebird bio Inc at Goldman Sachs Global Healthcare Conference Transcript

Jun 11, 2019 / 05:00PM GMT
Release Date Price: $76.68 (+0.13%)
Salveen Jaswal Richter
Goldman Sachs Group Inc., Research Division - VP

All right. Well, thank you, everyone, for joining us. I'm Salveen Richter, one of the biotechnology analysts at Goldman Sachs, and we're pleased to have the bluebird bio team here with us. So we have Chip Baird, CFO; and Dave Davidson, Chief Medical Officer.

Questions & Answers

Salveen Jaswal Richter;David M. Davidson
Goldman Sachs Group Inc., Research Division - VP;bluebird bio, Inc. - Chief Medical

Maybe to start here. You hosted an Analyst Day recently where you laid out kind of the early stage, next-generation pipeline that's following through your late-stage pipeline of 4 drugs here. Could you just walk us through, as we think about the evolution of bluebird, what your core focuses is going to be. A lot of these programs that came out were mostly oncology related. So is that really the way you see yourself progressing more versus severe genetic diseases? And what are you most excited about with regard to these programs and technologies?

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot